Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify the treatment of venous thromboembolism. METHODS: In this randomized, double-blind study, we compared apixaban (at a dose of 10 mg twice daily for 7 days, followed by 5 mg twice daily for 6 months) with conventional therapy (subcutaneous enoxaparin, followed by warfarin) in 5395 patients with acute venous thromboembolism. The primary efficacy outcome was recurrent symptomatic venous thromboembolism or death related to venous thromboembolism. The principal safety outcomes were major bleeding alone and major bleeding plus clinically relevant nonmajor bleeding. RESULTS: The primary efficacy outcome occurred in 59 of 2609 patients (2.3%) in the apixaban group, as compared with 71 of 2635 (2.7%) in the conventional-therapy group (relative risk, 0.84; 95% confidence interval [CI], 0.60 to 1.18; difference in risk [apixaban minus conventional therapy], -0.4 percentage points; 95% CI, -1.3 to 0.4). Apixaban was noninferior to conventional therapy (P<0.001) for predefined upper limits of the 95% confidence intervals for both relative risk (<1.80) and difference in risk (<3.5 percentage points). Major bleeding occurred in 0.6% of patients who received apixaban and in 1.8% of those who received conventional therapy (relative risk, 0.31; 95% CI, 0.17 to 0.55; P<0.001 for superiority). The composite outcome of major bleeding and clinically relevant nonmajor bleeding occurred in 4.3% of the patients in the apixaban group, as compared with 9.7% of those in the conventional-therapy group (relative risk, 0.44; 95% CI, 0.36 to 0.55; P<0.001). Rates of other adverse events were similar in the two groups. CONCLUSIONS: A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding (Funded by Pfizer and Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00643201).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
Citations
Cites
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
Apixaban for Extended Treatment of Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1207541 · Cited by 1,366
Self-citationPulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Farrington, C. P., & Manning, G. (1990) · Statistics in Medicine · doi:10.1002/sim.4780091208 · Cited by 657
Idraparinux versus Standard Therapy for Venous Thromboembolic Disease
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa064247 · Cited by 335
Cited by
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Konstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.-J., Harjola, V.-P., Huisman, M. V., Humbert, M., Jennings, C. S., Jiménez, D., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz405 · Cited by 4,916
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Konstantinides, S. V., Torbicki, A., Agnelli, G., Danchin, N., Fitzmaurice, D., Galiè, N., Gibbs, J. S. R., Huisman, M. V., Humbert, M., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu283 · Cited by 3,128
Self-citationSteffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy136 · Cited by 2,123
“This was in contrast to the reduced bleeding seen in the obese patient group in the AMPLIFY study of apixaban in the treatment of VTE.(330) Similarly in ROCKETAF, obese patients (BMI >_35 kg/m(2)) had a reduced stroke risk compared with the remainder of the cohort, and there was no interaction for the efficacy and saf…”
ResultSelf-citationEdoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
The Hokusai-VTE Investigators (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306638 · Cited by 1,869
Konstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.-J., Harjola, V.-P., Huisman, M. V., Humbert, M., Jennings, C. S., Jiménez, D., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01647-2019 · Cited by 1,619
“lactation, and in patients with antiphospholipid antibody syndrome.(260,261,312) 314 III C”
BackgroundOrtel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001830 · Cited by 1,489
Kaatz, S., Ahmad, D., Spyropoulos, A. C., & Schulman, S. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13140 · Cited by 1,419
Young, A. M., Marshall, A., Thirlwall, J., Chapman, O., Lokare, A., Hill, C., Hale, D., Dunn, J. A., Lyman, G. H., Hutchinson, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.8034 · Cited by 1,348
“9 Currently receiving cancer treatment§ 142 (70) 140 (69) Chemotherapy 120 (85) 113 (81) Radiotherapy 10 (7) 6 (4) Targeted therapy 22 (15) 21 (15) Endocrine therapy 15 (11) 15 (11) Primary tumor type Bladder 4 (2) 10 (5) Brain 2 (1) 1 (1) Breast 20 (10) 20 (10) Cancer unknown primary 3 (2) 3 (1) Chronic lymphoid leuk…”
Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., et al. (2021) · EP Europace · doi:10.1093/europace/euab065 · Cited by 1,132
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
Agnelli, G., Becattini, C., Meyer, G., Muñoz, A., Huisman, M. V., Connors, J. M., Cohen, A., Bauersachs, R., Brenner, B., Torbicki, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915103 · Cited by 1,067
Self-citationDeep vein thrombosis and pulmonary embolism
Di Nisio, M., van Es, N., & Büller, H. R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30514-1 · Cited by 994
Self-citationAntithrombotic Therapy for VTE Disease
Stevens, S. M., Woller, S. C., Kreuziger, L. B., Bounameaux, H., Doerschug, K., Geersing, G.-J., Huisman, M. V., Kearon, C., King, C. S., Knighton, A. J., et al. (2021) · Chest · doi:10.1016/j.chest.2021.07.055 · Cited by 1,043
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
Connolly, S. J., Crowther, M., Eikelboom, J. W., Gibson, C. M., Curnutte, J. T., Lawrence, J. H., Yue, P., Bronson, M. D., Lu, G., Conley, P. B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814051 · Cited by 960
Self-citationTreatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis
Schulman, S., Kakkar, A. K., Goldhaber, S. Z., Schellong, S., Eriksson, H., Mismetti, P., Christiansen, A. V., Friedman, J., Le Maulf, F., Peter, N., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.004450 · Cited by 923
“48, respectively).(20) There was never a risk estimate exceeding 1.”
BackgroundManagement of severe perioperative bleeding: Guidelines from the European Society of Anaesthesiology
Kozek-Langenecker, S. A., Afshari, A., Albaladejo, P., Santullano, C. A. A., De Robertis, E., Filipescu, D. C., Fries, D., Görlinger, K., Haas, T., Imberger, G., et al. (2013) · European Journal of Anaesthesiology · doi:10.1097/eja.0b013e32835f4d5b · Cited by 909
van Es, N., Coppens, M., Schulman, S., Middeldorp, S., & Büller, H. R. (2014) · Blood · doi:10.1182/blood-2014-04-571232 · Cited by 851
Self-citationKozek-Langenecker, S. A., Ahmed, A. B., Afshari, A., Albaladejo, P., Aldecoa, C., Barauskas, G., De Robertis, E., Faraoni, D., Filipescu, D. C., Fries, D., et al. (2017) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000000630 · Cited by 800
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors
Connolly, S. J., Milling, T. J., Eikelboom, J. W., Gibson, C. M., Curnutte, J. T., Gold, A., Bronson, M. D., Lu, G., Conley, P. B., Verhamme, P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607887 · Cited by 807
Self-citationKakkos, S. K., Gohel, M., Baekgaard, N., Bauersachs, R., Bellmunt-Montoya, S., Black, S. A., ten Cate-Hoek, A. J., Elalamy, I., Enzmann, F. K., Geroulakos, G., et al. (2021) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2020.09.023 · Cited by 743
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
Weitz, J. I., Lensing, A. W. A., Prins, M. H., Bauersachs, R., Beyer-Westendorf, J., Bounameaux, H., Brighton, T. A., Cohen, A. T., Davidson, B. L., Decousus, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700518 · Cited by 787
Self-citationFrontera, J. A., Lewin III, J. J., Rabinstein, A. A., Aisiku, I. P., Alexandrov, A. W., Cook, A. M., del Zoppo, G. J., Kumar, M. A., Peerschke, E. I. B., Stiefel, M. F., et al. (2016) · Neurocritical Care · doi:10.1007/s12028-015-0222-x · Cited by 706
“apixaban, and edoxaban), and secondary prevention of deep venous thrombosis or pulmonary embolism (rivaroxaban and apixaban only) [119–128].”
BackgroundNorthup, P. G., Garcia‐Pagan, J. C., Garcia‐Tsao, G., Intagliata, N. M., Superina, R. A., Roberts, L. N., Lisman, T., & Valla, D. C. (2021) · Hepatology · doi:10.1002/hep.31646 · Cited by 667
“The use of DOACs as therapy for PVT is now becoming commonplace despite the fact that large clinical trials of DOACs have excluded patients with PVT in the past.(193) Several retrospective, small studies are now published demonstrating the successful use of DOACs for this indication in patients without cirrhosis.”
BackgroundDirect Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges
Chen, A., Stecker, E., & A. Warden, B. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.017559 · Cited by 666
ATUALIZAÇÃO DA DIRETRIZ BRASILEIRA DE DISLIPIDEMIAS E PREVENÇÃO DA ATEROSCLEROSE - 2017
Faludi, A., Izar, M., Saraiva, J., Chacra, A., Bianco, H., Afiune Neto, A., Bertolami, A., Pereira, A., Lottenberg, A., Sposito, A., et al. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20170121 · Cited by 633
Farge, D., Frere, C., Connors, J. M., Ay, C., Khorana, A. A., Munoz, A., Brenner, B., Kakkar, A., Rafii, H., Solymoss, S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30336-5 · Cited by 651
Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019
Moores, L. K., Tritschler, T., Brosnahan, S., Carrier, M., Collen, J. F., Doerschug, K., Holley, A. B., Jimenez, D., Le Gal, G., Rali, P., et al. (2020) · Chest · doi:10.1016/j.chest.2020.05.559 · Cited by 638
Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial
McBane, R. D., Wysokinski, W. E., Le‐Rademacher, J. G., Zemla, T., Ashrani, A., Tafur, A., Perepu, U., Anderson, D., Gundabolu, K., Kuzma, C., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14662 · Cited by 591
Epidemiology and prevention of venous thromboembolism
Lutsey, P. L., & Zakai, N. A. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00787-6 · Cited by 507
Prins, M. H., Lensing, A. W., Bauersachs, R., van Bellen, B., Bounameaux, H., Brighton, T. A., Cohen, A. T., Davidson, B. L., Decousus, H., Raskob, G. E., et al. (2013) · Thrombosis Journal · doi:10.1186/1477-9560-11-21 · Cited by 551
Self-citationvan der Hulle, T., Kooiman, J., den Exter, P. L., Dekkers, O. M., Klok, F. A., & Huisman, M. V. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12485 · Cited by 536
Mismetti, P., Laporte, S., Pellerin, O., Ennezat, P.-V., Couturaud, F., Elias, A., Falvo, N., Meneveau, N., Quere, I., Roy, P.-M., et al. (2015) · JAMA · doi:10.1001/jama.2015.3780 · Cited by 489
Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH
Martin, K., Beyer‐Westendorf, J., Davidson, B. L., Huisman, M. V., Sandset, P. M., & Moll, S. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13323 · Cited by 445
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Akl, E. A., Kahale, L. A., Barba, M., Neumann, I., Labedi, N., Terrenato, I., Sperati, F., Muti, P., & Schünemann, H. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006650.pub4 · Cited by 428
Deep vein thrombosis: pathogenesis, diagnosis, and medical management
Stone, J., Hangge, P., Albadawi, H., Wallace, A., Shamoun, F., Knuttien, M. G., Naidu, S., & Oklu, R. (2017) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2017.09.01 · Cited by 381
“After more than a decade of research, multiple large-scale clinical trials have demonstrated comparable efficacy between the two drug classes (46,50,52,57,58,61,63).”
BackgroundWolberg, A. S., Rosendaal, F. R., Weitz, J. I., Jaffer, I. H., Agnelli, G., Baglin, T., & Mackman, N. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.6 · Cited by 369
Self-citationManagement of venous thrombo-embolism: an update
Konstantinides, S., & Torbicki, A. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu243 · Cited by 383
“The Apixaban for the Initial Management of Pulmonary Embolism andDVTasFirst-line Therapy (AMPLIFY) study compared single-oral drug treatment with the direct factor Xa inhibitor apixaban with the standard therapy in 5395 patients with acute VTE.(52) Apixaban was non-inferior to conventional treatment for the primary ef…”
MethodInfluentialApixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
Byon, W., Garonzik, S., Boyd, R. A., & Frost, C. E. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00775-z · Cited by 348
“Further, no meaningful differences were seen between male and female subjects in the primary efficacy or safety outcomes in the key phase III trials for apixaban [5, 6, 10, 11, 44].”
BackgroundNarouze, S., Benzon, H. T., Provenzano, D. A., Buvanendran, A., De Andres, J., Deer, T. R., Rauck, R., & Huntoon, M. A. (2015) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000223 · Cited by 362
Huisman, M. V., Barco, S., Cannegieter, S. C., Le Gal, G., Konstantinides, S. V., Reitsma, P. H., Rodger, M., Noordegraaf, A. V., & Klok, F. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.28 · Cited by 336
Guidance for the treatment of deep vein thrombosis and pulmonary embolism
Streiff, M. B., Agnelli, G., Connors, J. M., Crowther, M., Eichinger, S., Lopes, R., McBane, R. D., Moll, S., & Ansell, J. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1317-0 · Cited by 344
“Apixaban, an oral direct factor Xa inhibitor, was compared to conventional therapy (enoxaparin followed by warfarin) for treatment of VTE in the AMPLIFY study and to placebo in the AMPLIFY EXT trial [44, 45].”
MethodSelf-citationFarge, D., Bounameaux, H., Brenner, B., Cajfinger, F., Debourdeau, P., Khorana, A. A., Pabinger, I., Solymoss, S., Douketis, J., & Kakkar, A. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30369-2 · Cited by 347
Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment
Burnett, A. E., Mahan, C. E., Vazquez, S. R., Oertel, L. B., Garcia, D. A., & Ansell, J. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1310-7 · Cited by 333
Management of Pulmonary Embolism
Konstantinides, S. V., Barco, S., Lankeit, M., & Meyer, G. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.11.061 · Cited by 330
Acute Pulmonary Embolism: A Review
Freund, Y., Cohen-Aubart, F., & Bloom, B. (2022) · JAMA · doi:10.1001/jama.2022.16815 · Cited by 301
Majeed, A., Ågren, A., Holmström, M., Bruzelius, M., Chaireti, R., Odeberg, J., Hempel, E.-L., Magnusson, M., Frisk, T., & Schulman, S. (2017) · Blood · doi:10.1182/blood-2017-05-782060 · Cited by 326
Chai-Adisaksopha, C., Crowther, M., Isayama, T., & Lim, W. (2014) · Blood · doi:10.1182/blood-2014-07-590323 · Cited by 326
Erkan, D., Aguiar, C. L., Andrade, D., Cohen, H., Cuadrado, M. J., Danowski, A., Levy, R. A., Ortel, T. L., Rahman, A., Salmon, J. E., et al. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.053 · Cited by 322
“The efficacy of ODIs for venous thromboembolism (VTE) has been demonstrated in large Phase III clinical trials [7–10].”
BackgroundVeitch, A. M., Vanbiervliet, G., Gershlick, A. H., Boustiere, C., Baglin, T. P., Smith, L.-A., Radaelli, F., Knight, E., Gralnek, I. M., Hassan, C., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-311110 · Cited by 296
Wang, X., Tirucherai, G., Marbury, T. C., Wang, J., Chang, M., Zhang, D., Song, Y., Pursley, J., Boyd, R. A., & Frost, C. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.628 · Cited by 286
“Apixaban is an oral, selective, direct reversible inhibitor of the coagulation factor Xa (FXa), approved in a number of countries for thromboprophylaxis in patients who have undergone elective hip or knee replacement surgery, for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fib…”
BackgroundLeft Ventricular Thrombus After Acute Myocardial Infarction: Screening, Prevention, and Treatment
McCarthy, C. P., Vaduganathan, M., McCarthy, K. J., Januzzi, J. L., Bhatt, D. L., & McEvoy, J. W. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.1086 · Cited by 268
Direct Oral Anticoagulants in Patients With VTE and Cancer
Vedovati, M. C., Germini, F., Agnelli, G., & Becattini, C. (2015) · Chest · doi:10.1378/chest.14-0402 · Cited by 270
Self-citationDiagnosis and Treatment of Lower Extremity Venous Thromboembolism: A Review
Chopard, R., Albertsen, I. E., & Piazza, G. (2020) · JAMA · doi:10.1001/jama.2020.17272 · Cited by 244
Connors, J. M., Brooks, M. M., Sciurba, F. C., Krishnan, J. A., Bledsoe, J. R., Kindzelski, A., Baucom, A. L., Kirwan, B.-A., Eng, H., Martin, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.17272 · Cited by 251
Aspirin for the Prevention of Recurrent Venous Thromboembolism: The INSPIRE Collaboration
Simes, J., Becattini, C., Agnelli, G., Eikelboom, J. W., Kirby, A. C., Mister, R., Prandoni, P., & Brighton, T. A. (2014) · Circulation · doi:10.1161/circulationaha.114.008828 · Cited by 262
“PE only 231 (28) 55 (14) 137 (23) 149 (24)”
Self-citationPulmonary embolism: update on management and controversies
Duffett, L., Castellucci, L. A., & Forgie, M. A. (2020) · BMJ · doi:10.1136/bmj.m2177 · Cited by 232
Intagliata, N. M., Henry, Z. H., Maitland, H., Shah, N. L., Argo, C. K., Northup, P. G., & Caldwell, S. H. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-4012-2 · Cited by 245
Couturaud, F., Sanchez, O., Pernod, G., Mismetti, P., Jego, P., Duhamel, E., Provost, K., dit Sollier, C. B., Presles, E., Castellant, P., et al. (2015) · JAMA · doi:10.1001/jama.2015.7046 · Cited by 249
Steffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Georg Haeusler, K., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · EP Europace · doi:10.1093/europace/euy054 · Cited by 247
Self-citationSharma, M., Cornelius, V. R., Patel, J. P., Davies, J. G., & Molokhia, M. (2015) · Circulation · doi:10.1161/circulationaha.114.013267 · Cited by 243
“In the Amplify, Einstein-DVT, and Einstein-PE, they received a higher dose of DOAC for a short period prior to initiation of a standard dose.(19,20,31) Also, because bleeding definitions were not mutually exclusive within trials, some estimates of risk by bleeding classification were difficult to interpret.”
BackgroundNCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018
Streiff, M. B., Holmstrom, B., Angelini, D., Ashrani, A., Bockenstedt, P. L., Chesney, C., Fanikos, J., Fenninger, R. B., Fogerty, A. E., Gao, S., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0084 · Cited by 242
Ageno, W., Mantovani, L. G., Haas, S., Kreutz, R., Monje, D., Schneider, J., van Eickels, M., Gebel, M., Zell, E., & Turpie, A. G. G. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00257-4 · Cited by 243
Trends in the prescription of novel oral anticoagulants in UK primary care
Loo, S. Y., Dell'Aniello, S., Huiart, L., & Renoux, C. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13299 · Cited by 240
Treatment of Venous Thromboembolism
Wells, P. S., Forgie, M. A., & Rodger, M. A. (2014) · JAMA · doi:10.1001/jama.2014.65 · Cited by 237
Smythe, M. A., Priziola, J., Dobesh, P. P., Wirth, D., Cuker, A., & Wittkowsky, A. K. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1315-2 · Cited by 231
Pros and cons of new oral anticoagulants
Bauer, K. A. (2013) · Hematology · doi:10.1182/asheducation-2013.1.464 · Cited by 226
Veitch, A., Vanbiervliet, G., Gershlick, A., Boustiere, C., Baglin, T., Smith, L.-A., Radaelli, F., Knight, E., Gralnek, I., Hassan, C., et al. (2016) · Endoscopy · doi:10.1055/s-0042-102652 · Cited by 226
Posch, F., Königsbrügge, O., Zielinski, C., Pabinger, I., & Ay, C. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.07.011 · Cited by 215
“Recently, direct-acting oral anticoagulants (DOACs) that directly inhibit either factor Xa (apixaban, edoxaban, and rivaroxaban) or thrombin (dabigatran) have been introduced as novel agents for treatment of VTE [11–14].”
BackgroundTwine, C. P., Kakkos, S. K., Aboyans, V., Baumgartner, I., Behrendt, C.-A., Bellmunt-Montoya, S., Jilma, B., Nordanstig, J., Saratzis, A., Reekers, J. A., et al. (2023) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2023.03.042 · Cited by 197
New Oral Anticoagulants and the Cancer Patient
Short, N. J., & Connors, J. M. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0239 · Cited by 204
Cohen, A. T., Hamilton, M., Mitchell, S. A., Phatak, H., Liu, X., Bird, A., Tushabe, D., & Batson, S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0144856 · Cited by 198
“This was reported in the trial publications as follows: AMPLIFY [21]–adjudicated composite of recurrent VTE or death related to VTE.”
BackgroundMethodResultInfluentialSelf-citationSterne, J. A., Bodalia, P. N., Bryden, P. A., Davies, P. A., López-López, J. A., Okoli, G. N., Thom, H. H., Caldwell, D. M., Dias, S., Eaton, D., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21090 · Cited by 198
Agnelli, G., Buller, H. R., Cohen, A., Gallus, A. S., Lee, T. C., Pak, R., Raskob, G. E., Weitz, J. I., & Yamabe, T. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13153 · Cited by 197
Self-citationStreiff, M. B., Holmstrom, B., Angelini, D., Ashrani, A., Buckner, T., Diep, R., Fertrin, K. Y., Fogerty, A. E., Crestani, N. G., Gangaraju, R., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0046 · Cited by 184
Deep vein thrombosis: update on diagnosis and management
Kruger, P. C., Eikelboom, J. W., Douketis, J. D., & Hankey, G. J. (2019) · Medical Journal of Australia · doi:10.5694/mja2.50201 · Cited by 188
Chai‐Adisaksopha, C., Hillis, C., Isayama, T., Lim, W., Iorio, A., & Crowther, M. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13139 · Cited by 190
Treatment of cancer-associated thrombosis
Lee, A. Y. Y., & Peterson, E. A. (2013) · Blood · doi:10.1182/blood-2013-04-460162 · Cited by 183
Almutairi, A. R., Zhou, L., Gellad, W. F., Lee, J. K., Slack, M. K., Martin, J. R., & Lo-Ciganic, W.-H. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.05.358 · Cited by 171
Woller, S. C., Stevens, S. M., Kaplan, D., Wang, T.-F., Branch, D. W., Groat, D., Wilson, E. L., Armbruster, B., Aston, V. T., Lloyd, J. F., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021005808 · Cited by 166
Yaghi, S. R., Shu, L., Bakradze, E., Omran, S. S., Giles, J. A., Amar, J. Y., Henninger, N., Elnazeir, M., Liberman, A. L., Moncrieffe, K., et al. (2022) · Stroke · doi:10.1161/strokeaha.121.037541 · Cited by 190
Carrier, M., Cameron, C., Delluc, A., Castellucci, L., Khorana, A. A., & Lee, A. Y. Y. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.09.039 · Cited by 172
Review of the cost of venous thromboembolism
Fernandez, M., Hogue, S. L., Preblick, R., & Kwong, W. J. (2015) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s85635 · Cited by 171
The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis
Hum, J., Shatzel, J. J., Jou, J. H., & Deloughery, T. G. (2017) · European Journal of Haematology · doi:10.1111/ejh.12844 · Cited by 170
Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban
Chang, M., Yu, Z., Shenker, A., Wang, J., Pursley, J., Byon, W., Boyd, R. A., LaCreta, F., & Frost, C. E. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.633 · Cited by 171
Keragala, C. B., Draxler, D. F., McQuilten, Z. K., & Medcalf, R. L. (2018) · British Journal of Haematology · doi:10.1111/bjh.15062 · Cited by 170
“These have been clinically proven to provide non-inferior anti-thrombotic therapy compared to warfarin with often, a more favourable bleeding profile (Connolly et al, 2009; Schulman et al, 2009; The EINSTEIN Investigators, 2010, 2012; Agnelli et al, 2013; Madan et al, 2016).”
BackgroundNarouze, S., Benzon, H. T., Provenzano, D., Buvanendran, A., De Andres, J., Deer, T., Rauck, R., & Huntoon, M. A. (2017) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000700 · Cited by 164
Cohen, H., Cuadrado, M. J., Erkan, D., Duarte‐García, A., Isenberg, D. A., Knight, J. S., Ortel, T. L., Rahman, A., Salmon, J. E., Tektonidou, M. G., et al. (2020) · Lupus · doi:10.1177/0961203320950461 · Cited by 181
Johnson, J. A., & Cavallari, L. H. (2015) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2014.09.001 · Cited by 164
Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism
Witt, D. M., Clark, N. P., Kaatz, S., Schnurr, T., & Ansell, J. E. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1319-y · Cited by 161
“Compared to warfarin-based therapy (with heparin or LMWH overlap during initiation), apixaban resulted in a reduction in both major and clinically relevant non-major bleeding during treatment for acute VTE [20].”
MethodDufrost, V., Risse, J., Reshetnyak, T., Satybaldyeva, M., Du, Y., Yan, X.-X., Salta, S., Gerotziafas, G., Jing, Z.-C., Elalamy, I., et al. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.04.009 · Cited by 161
Castellucci, L. A., Cameron, C., Le Gal, G., Rodger, M. A., Coyle, D., Wells, P. S., Clifford, T., Gandara, E., Wells, G., & Carrier, M. (2014) · JAMA · doi:10.1001/jama.2014.10538 · Cited by 162
Barco, S., Schmidtmann, I. M., Ageno, W., Bauersachs, R. M., Becattini, C., Bernardi, E., Beyer‐Westendorf, J., Bonacchini, L., Brachmann, J., Christ, M., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz367 · Cited by 184
Frost, C. E., Byon, W., Song, Y., Wang, J., Schuster, A. E., Boyd, R. A., Zhang, D., Yu, Z., Dias, C., Shenker, A., et al. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12541 · Cited by 160
Raskob, G. E., van Es, N., Segers, A. E. M., Angchaisuksiri, P., Oh, D., Boda, Z., Lyons, R. M., Meijer, K., Gudz, I., Weitz, J. I., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)30057-6 · Cited by 167
Self-citationvan der Hulle, T., den Exter, P. L., Kooiman, J., van der Hoeven, J. J. M., Huisman, M. V., & Klok, F. A. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12605 · Cited by 164
Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer
Kahale, L. A., Hakoum, M. B., Tsolakian, I. G., Alturki, F., Matar, C. F., Terrenato, I., Sperati, F., Barba, M., Yosuico, V. E. D., Schünemann, H. J., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006650.pub5 · Cited by 170
2014 ESC Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism
Konstantinides, S., Torbicki, A., Agnelli, G., Danchin, N., Fitzmaurice, D. A., Galiè, N., Gibbs, J. S. R., Huisman, M., Humbert, M. J. C., Kucher, N., et al. (2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2014.12.002 · Cited by 153
“) with conventional therapy (enoxaparin/warfarin) in 5395 patients with acute VTE, 1836 of whom presented with PE (Table 11).(297) The primary efficacy outcome was recurrent symptomatic VTE or death related to VTE.”
Self-citationReversal of anticoagulants: an overview of current developments
Thiele, T., Selleng, K., & Greinacher, A. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-11-0982 · Cited by 161
Metadata
- Authors
- Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., & Weitz, J. I.
- Affiliations
- University of Perugia (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- King's College Hospital (GB)
- Pfizer (United States) (US)
- Flinders University (AU)
- University of Oklahoma Health Sciences Center (US)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-08-29
- Volume
- 369
- Issue
- 9
- Pages
- 799-808
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2166402206
- Cited by
- 2,324
- References
- 13
- Citations by year
- 2026: 109 · 2025: 101 · 2024: 134 · 2023: 134 · 2022: 162 · 2021: 193 · 2020: 224 · 2019: 193 · 2018: 213 · 2017: 191 · 2016: 234 · 2015: 198 · 2014: 184 · 2013: 51
- FWCI
- 194.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- apixaban, acute venous thromboembolism, factor Xa inhibitors, oral anticoagulation, enoxaparin, warfarin, recurrent venous thromboembolism, major bleeding, non-inferiority, fixed-dose regimen, direct oral anticoagulants, anticoagulation duration, venous thromboembolism
- MeSH terms
- Acute Disease, Administration, Oral, Adult, Aged, Anticoagulants, Double-Blind Method, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pyrazoles, Pyridones, Warfarin, Treatment Outcome, Enoxaparin, Kaplan-Meier Estimate, Venous Thromboembolism, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.